One Step Closer To A Malaria Vaccine

BMI View : Communicable diseases will remain a significant health burden over the next two decades forcing companies to adopt low-price, high-volume business models as the burden is overwhelmingly concentrated in low income countries. This will continue to limit revenue earning opportunities for companies whose product portfolios contain medicines for the treatment of long-term diseases.

Multinational drugmaker GlaxoSmithKline is to seek marketing approval for the world's first malaria vaccine. Results from a large-scale phase III trial show that the most clinically advanced malaria vaccine candidate, RTS,S, continued to protect young children and infants from clinical malaria up to 18 months after vaccination. Based on this data, GSK now intends to submit, in 2014, a regulatory application to the European Medicines Agency (EMA).

GSK has been conducting clinical trials for the vaccine in eleven African research centres in seven African countries, in conjunction with, the PATH Malaria Vaccine Initiative (MVI), with grant funding from the Bill & Melinda Gates Foundation to MVI.

Dominated By Africa
Estimated Malaria Cases

or Register now for free to read the full article

This article is tagged to:
Sector: Pharmaceuticals & Healthcare
Geography: Global

Access all of our latest analysis, data and forecasts - request a trial